Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
Konstantina DrelliaLili KokotiChristina I DeligianniDimitrios PapadopoulosDimos-Dimitrios D MitsikostasPublished in: Cephalalgia : an international journal of headache (2021)
This analysis showed that anti-CGRP mAbs exhibit a more favourable benefit-risk ratio than established treatments for episodic and chronic migraine. Head-to-head studies are needed to confirm these results.